Compare Mattel Inc (MAT) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mattel Inc vs Mesoblast Limited — how do they compare? Mattel Inc trades at $17.1 (market cap $4.74B), while Mesoblast Limited trades at $14.26 (market cap $1.75B). The key difference: Mattel Inc is far larger — about 2.7× Mesoblast Limited's market cap, and Mattel Inc is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Mattel Inc for 97 Days and Mesoblast Limited for 14 Days on average.
| MAT | MESO | |
|---|---|---|
Market Cap | $4.74B | $1.75B |
Volume | 11,809,722 | 239,027 |
Sector | Consumer Cyclical | Health |
52-Week High | $22.16 | $20.96 |
52-Week Low | $12.66 | $13.19 |
Typical Hold Time | 97 Days | 14 Days |
Enterprise Value | $6.96B | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mattel (MAT) trades at $16.37, up 2.76% on the day, with a bullish technical signal and strong profitability metrics including a 20.5% ROE and 7.78% net margin. Recent news highlights takeover interest from Authentic Brands Group and a CEO transition to Roger Lynch. Cash flow turned negative in 2025 at -$145M, but revenue remains stable around $5.3B.
The stock presents a mixed outlook: analyst consensus is a Buy with a $15.00 price target, but recent earnings misses and negative cash flow pose risks. Upside is supported by takeover speculation and solid brand portfolio, while execution under new leadership and Barbie sales trends are key watchpoints.
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mattel Inc
Mattel markets toy products that are sold to its wholesale customers and direct to retail consumers. The company offers products for children and families, including toys for infants and preschoolers, girls and boys, youth electronics, handheld and other games, puzzles, educational toys, media-driven products, and plush and fashion-related toys. Mattel's owned portfolio includes Barbie, Hot Wheels, Fisher-Price, Thomas & Friends, and American Girl. In addition, it currently manufactures toy products for its segments both internally and externally (through manufacturing partners). Just over half of its net sales are in North America, while the remainder stem from international markets.
Read more on MAT →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
